All terms in BAO
| Label | Id | Description |
|---|---|---|
| ULight poly-GT | BAO_0001042 | |
| Ubiquitin vinyl sulfone | BAO_0001041 | [For use in the detection and identification of deubiquitinylating enzymes] |
| structure based virtual screening | BAO_0002372 | |
| EC 1.* (oxidoreductase) inhibitor | CHEBI_76725 | |
| Monte Carlo minimization method | BAO_0002375 | |
| EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor | CHEBI_76727 | |
| internal coordinate mechanics method | BAO_0002376 | |
| Monte Carlo simulated annealing | BAO_0002377 | |
| EC 1.3.* (oxidoreductase acting on donor CH-CH group) inhibitor | CHEBI_76729 | |
| AutoDock docking method | BAO_0002378 | |
| male | PATO_0000384 | [A biological sex quality inhering in an individual or a population whose sex organs contain only male gametes.] |
| biological sex | PATO_0000047 | [An organismal quality inhering in a bearer by virtue of the bearer's ability to undergo sexual reproduction in order to differentiate the individuals or types involved.] |
| EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor | CHEBI_76730 | |
| female | PATO_0000383 | [A biological sex quality inhering in an individual or a population that only produces gametes that can be fertilised by male gametes.] |
| EC 1.5.* (oxidoreductase acting on donor CH-NH group) inhibitor | CHEBI_76731 | |
| LRH-1 antagonist | CHEBI_136580 | |
| disease of anatomical entity | DOID_7 | [A disease that manifests in a defined anatomical structure.] |
| U87-EGFRvIII cell | CLO_0037276 | |
| compound fluorescence assay | BAO_0001099 | [This assay is performed to identify compounds that have a property of auto-fluorescence.] |
| artifact assay | BAO_0000684 | [Artifact (aka 'artefact') assays are performed to help interpret HTS results by testing whether a 'hit' might be due to some inherent physicochemical property of the compound or perturbagen alone - in the absence of any target. Examples include fluorescence, or inhibition of the enzyme luciferase, which are part of common assay designs; another example is solubility (e.g., if a compound aggregates and interferes with an assay readout).] |